Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study

Despite the retrospective, nonrandomized design, the temporal association between treatment and remission supports an effect of anti-CD38 monoclonal antibody alone or in combination with anti-CD20. Treatment is safe and may confer enhanced efficacy over standard approaches. Prospective, mechanistic studies are warranted to validate these findings and delineate the immunopathogenesis of FSGS recurrence.

Authors

Institutions

Publication Details

Journal
Transplantation Direct
Published
2026-01-20
DOI
https://doi.org/10.1097/txd.0000000000001908
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study

Xhuliana Kajana, Alessandra Palmisano, Andrea Angeletti, Ali Poyan Mehr et al.
Transplantation Direct
Renal Diseases and Glomerulopathies
article

Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study

Xhuliana Kajana, Alessandra Palmisano, Andrea Angeletti, Ali Poyan Mehr, Nelson Goes, F. Vincenti, Micaela Gentile, Gian Marco Ghiggeri, Gianluca Caridi, Gabriele Mortari, Paolo Cravedi, Alberto Magnasco, Nicola Bossini, Rohan V. Mehta, Agnese Spennacchio, Giorgia Comai, Carolina Bigatti, Nicolas Bouvier, Frank E. Hullekes, Enrico E. Verrina, Gaetano La Manna, Simona Barbuto, Umberto Maggiore, Leonardo V. Riella
article en

Abstract

Despite the retrospective, nonrandomized design, the temporal association between treatment and remission supports an effect of anti-CD38 monoclonal antibody alone or in combination with anti-CD20. Treatment is safe and may confer enhanced efficacy over standard approaches. Prospective, mechanistic studies are warranted to validate these findings and delineate the immunopathogenesis of FSGS recurrence.

Transplantation DirectVol. 12(2)
University of Parma (IT), Harvard University (US), Illinois College (US), University of California, San Francisco (US), Istituto Giannina Gaslini (IT), University of Florida (US), University of Illinois Chicago (US), Massachusetts General Hospital (US), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Azienda USL di Bologna (IT), Kaiser Permanente San Francisco Medical Center (US), Azienda Socio Sanitaria Territoriale Lariana (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), University of Brescia (IT), University of Bologna (IT), Université de Caen Normandie (FR), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Openalex Percentile: Top 86%
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.